Lymphoblast biology and outcome among children with down syndrome and ALL treated on CCG-1952

Mylène Bassal, Mei K. La, James A. Whitlock, Harland N. Sather, Nyla A. Heerema, Paul S. Gaynon, Linda C. Stork

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Background. Patients with Down syndrome (DS) and standard risk (SR) acute lymphoblastic leukemia (ALL-DS) are reported to have inferior event free (EFS) and overall survival (OS) compared to patients without DS (ALL-NDS). Procedure. We compared the prevalence of favorable and unfavorable clinical and biologic features, toxicity and outcome within the ALL-DS and ALL-NDS cohorts of 2,174 eligible patients with SR-ALL enrolled on CCG-1952. Results. Fifty-nine patients (3%) had ALL-DS. DS patients were less likely to have either favorable (hyperdiploidy, triple trisomy of chromosomes 4, 10, and 17, TEL-AML1 rearrangement) or unfavorable (T-cell ALL, hypodiploidy, adverse translocations) biologic features. Toxicity occurred significantly more often and number of days hospitalized was significantly greater in ALL-DS than in ALL-NDS. ALL-DS patients had an inferior 4-year EFS compared to the NDS cohort. However, EFS was equivalent when the comparison excluded ALL-NDS with favorable biologic features. OS was significantly inferior for ALL-DS. Conclusions. The absence of favorable biologic features within ALL-DS contributes to the difference in EFS previously observed between DS and NDS SR-ALL cohorts.

Original languageEnglish (US)
Pages (from-to)21-28
Number of pages8
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jan 2005


  • Acute lymphoblastic leukemia
  • Biology
  • Down syndrome
  • Outcome
  • Prognostic features
  • Toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Lymphoblast biology and outcome among children with down syndrome and ALL treated on CCG-1952'. Together they form a unique fingerprint.

Cite this